LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced the pricing of an underwritten public offering of 979,592 shares of its common stock at $122.50 per share. The Company has granted the underwriters for the offering a 30-day option to purchase up to 146,938 additional shares of common stock at the public offering price, less the underwriting discount. The offering is expected to close on or about February 14, 2014.
Help employers find you! Check out all the jobs and post your resume.
